NPHC News Alert Nutra Pharma Corp (NPHC) 0.0068 10/15/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nutra Pharma Corp (NPHC) 0.0068 $NPHC

Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)

BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.

Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.

Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.

Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.

Myasthenia Gravis - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z232kc/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Grifols, S.A. - Astellas Pharma Inc. - Nutra Pharma Corporation - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Cytokinetics, Inc. - HanAll Biopharma Co., Ltd. - CuraVac, Inc. - Biokine Therapeutics Ltd. - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/z2...nia_gravis
CYTK: 3.27 (unch), ALXN: 157.33 (-2.13), GSK: 42.57 (-1.11)

Emerging Market Companies and Investor Updates Provided by BrokerBank Securities, Inc.
PR Newswire - Thu Jun 26, 6:00AM CDT
NYBD Holding, Inc. (OTCBB: NYBD) has filed for a name change and it has been accepted. The company will now be trading under (AQUA), will be named Pleasant Kids, Inc. and the company is expecting the name and symbol change to take affect within the next few business days.

Nutra Pharma reports airing of OTC Pain Reliever Nyloxin commercials on television
M2 - Thu Jun 26, 5:04AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) disclosed on Wednesday that MyNyloxin.com has begun airing television commercials of its OTC Pain Reliever Nyloxin to help grow sales and increase public awareness.

Nutra Pharma Announces Nyloxin Television Commercial Rollout
Marketwire - Wed Jun 25, 9:10AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), has begun airing television commercials as of Monday, June 23rd. The advertisements focus on the benefits of Nyloxin(R). The first contract has already begun and includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE. Starting June 30, the commercials will begin airing in the New York and New Jersey markets with a rollout to the national stage in the coming weeks.

Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
Marketwire - Wed Jun 25, 8:25AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel has completed their work on a series of commercials to start airing in the month of June. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.

Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GSK: 42.57 (-1.11)

Myasthenia Gravis - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz5swx/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H2 2013" report to their offering. 'Myasthenia Gravis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis. Scope - A snapshot of the global therapeutic scenario for Myasthenia Gravis. - A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned GlaxoSmithKline plc Grifols, S.A. Astellas Pharma Inc. Nutra Pharma Corporation Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Cytokinetics, Incorporated HanAll Biopharma Co., Ltd. CuraVac, Inc. Biokine Therapeutics Ltd. Toleranzia AB Varleigh Immuno-Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/rz...nia_gravis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CYTK: 3.27 (unch), ALXN: 157.33 (-2.13), GSK: 42.57 (-1.11)

New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
SGYP: 2.69 (+0.02), CVM: 0.76 (unch), GSK: 42.58 (-1.10), SVA: 5.26 (+0.20), AGEN: 2.85 (+0.13), VICL: 1.24 (+0.07), FLML: 12.52 (+0.04), MRK: 54.71 (-1.62), NVS: 85.20 (-1.67)

Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC" program, Front Street Capital 2004 (the "Manager" has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund" .

Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CYTK: 3.27 (unch), BIIB: 302.94 (+1.36), GSK: 42.57 (-1.11), BCLI: 3.40 (-0.24), QCOR: 93.60 (+1.52), ISIS: 37.36 (+0.52), NVS: 85.20 (-1.67), CUR: 2.84 (+0.03)

Nutra Pharma Announces Delivery of Nyloxin(TM) to New Vitality
Business Wire - Thu Aug 29, 7:30AM CDT
Nutra Pharma Corporation (OTCQB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has placed and received their first order of the Company's all-natural, non-addictive pain reliever, Nyloxin(R). The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product.

Nutra Pharma Corporation begins registration process in South Africa of homeopathic pain drug Nyloxin
M2 - Fri Aug 23, 4:09AM CDT
Biotechnology company Nutra Pharma Corporation (OTC Markets:NPHC) reported on Thursday the start of the registration process in South Africa of its homeopathic chronic pain drug Nyloxin.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 202

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 0

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 39

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 77

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Settles SEC Investigation While Strengthening Operations

Updated Category News Views 215

BD Reaches Settlement with the SEC BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has announced a significant agreement to resolve an investigation by the U.S. Securities and Exchange Commission (SEC). This follows concerns regarding prior public disclosures related to the BD Alaris™ System. Key Details of the Resolution The...

Continue Reading
Seizing the Managed Detection and Response Market Opportunity

Updated Category News Views 232

Unlocking the Managed Detection and Response Market Potential Middleton, Massachusetts – QKS Group, a leading market intelligence and advisory firm, recently released an insightful report on the global Managed Detection and Response (MDR) Market. This comprehensive analysis targets industry leaders eager to tap into a rapidly growing sector. According to their findings,...

Continue Reading
Expanding Horizons: Coldwell Banker's Venture into Africa

Updated Category News Views 94

Coldwell Banker Real Estate's New Milestone Coldwell Banker Tanzania and Zanzibar have officially joined the growing network of Coldwell Banker Real Estate LLC, marking an exciting expansion into Africa. This new master franchise embodies the brand’s ongoing commitment to deliver top-tier real estate services on an international scale. Seizing Growing Markets The real...

Continue Reading
Automotive Grade Linux Unveils SoDeV Platform for Advancements

Updated Category News Views 289

Automotive Grade Linux Introduces SoDeV for Software Defined Vehicles In an exciting development for the automotive industry, Automotive Grade Linux (AGL) has launched SoDeV, an open-source reference platform aimed at significantly enhancing the development of Software Defined Vehicles (SDVs). This innovative platform allows developers to focus on software-first...

Continue Reading
Exploring Promising Tech Stocks Ahead of Future Opportunities

Updated Category News Views 257

Opportunity in Oversold Tech Stocks The information technology sector is witnessing a notable shift, with several stocks currently considered undervalued. These oversold stocks represent potential opportunities for savvy investors looking to capitalize on future growth. By focusing on these stocks, investors can identify undervalued companies that have the potential for...

Continue Reading